Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12.01 USD | +3.53% | +2.74% | +128.33% |
07/05 | Canaccord Genuity Adjusts Price Target on Stoke Therapeutics to $20 From $21, Maintains Buy Rating | MT |
06/05 | Earnings Flash (STOK) STOKE THERAPEUTICS Reports Q1 Revenue $4.2M | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+128.33% | 626M | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- STOK Stock
- News Stoke Therapeutics, Inc.
- Credit Suisse Lowers Stoke Therapeutics' Price Target to $28 From $32, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating